AI in Pharma Summit 2019

3rd Annual Edition

Data-Driven, People-Powered.

Unlocking the Full Potential of AI in Drug Discovery and Development

October 9th, 2019  |  Boston, MA.
Partners
Partners

Key Features of AI in Pharma 2019

Pioneering Speaker Faculty 

High-Quality Data Infrastructure, the “Right” use of AI and Machine Learning will all be put under the microscope by key opinion leaders of the industry.

One Impactful Day

We know you’re busy people. That’s why the AI in Pharma Summit is purposely constructed as a one-day feast of inspiring learning with a jam-packed agenda.

Senior-Level Networking

With speed-networking, hands-on workshops and long-table lunches the order of the day, meet with key decision-makers and AI champions in this purpose-built, intimate setting. 

Members of the AI in Pharma Summit Community

Expert Speaker Faculty

Vanita Sood

Global Head of Drug Structure, Prediction & Design, EMD Serono

As Global Head of Design, Structure, Prediction & Data science (DSPD), Vanita supports drug discovery (small molecule and biologics) with a global team of computational chemists, structural biologists, computational protein engineers, and data scientists.

Calum Macrae

Vice Chair for Scientific Innovation, Brigham and Women's Hospital & Harvard Medical School

Prasanna Rao

Head, A.I. and Data Science, Data Monitoring and Management, Pfizer

Brian Martin

Head of AI, AbbVie

Pat Walters

Senior Vice President, Computation, Relay Therapeutics

Pat Walters is SVP of Computation at Relay Therapeutics in Cambridge, MA. His group focuses on novel applications of computational methods that integrate computer simulations and experimental data to provide insights that drive drug discovery programs. Prior to joining Relay, Pat spent more than 20 years at Vertex Pharmaceuticals where he was Global Head of Modeling & Informatics.

Lina Williamson

Founder & Chief Innovation Officer, Translational Medicine Accelerator

Dr Williamson holds a DVM in animal dermatology and a PhD in human molecular and cellular dermato-pathology of autoimmune skin diseases from the University of Bern in Switzerland. She initiated her career at Novartis Pharmaceuticals in Switzerland where she had the opportunity to create and lead the Animal Dermatology Research group at Novartis Animal Health. Lina was later transferred to Boston in an international assignment to the Novartis Institutes for Biomedical Research (NIBR) as part of a cross-divisional business development team. She later joined NIBR’s Strategic Alliances team where she was responsible for leading the global outreach and scouting for innovation efforts from academic institutions, including academic incubators and startup companies. During that time, she developed interest on cutting edge technologies in the biomedical engineering field. That interest led her to join a startup company - Emulate Inc., derived from Harvard University’s Wyss Institute, focused on the development of Organs-on-Chips - and be part of the initial company creation team. Dr. Williamson joined the Brigham and Women’s Hospital in 2015, initially supporting the Brigham Research Institute as Innovation Strategists. Her entrepreneurial and strategic thinking & execution style, combined with more than twelve years of experience in the Pharma/Biotech industry, led her to take the challenge of create and establish the BWH Translational Accelerator, an initiative to support and speed up the transition of BWH’s innovation with commercial potential from bench to bed. Dr. Williamson currently serves as Founder, President & Chief Innovation Officer of the Translational Medicine Accelerator (TMA), a private biomedical development company formed to accelerate medical innovation that serves patients with unmet needs. Lina is also part of the NIH National Networks of Mentors in Entrepreneurship, a mentor for the post-doc program at Boston Children’s Hospital and supports entrepreneurship education programs from the Harvard Catalyst (Harvard Medical School).

Leo Rodrigues

Vice President, AI & Machine Learning, Berg Health

Lina Nilsson

Senior Director of Data Science Product, Recursion Pharmaceuticals

Lina Nilsson is Senior Director of Data Science Product at Recursion Pharmaceuticals, a company that is reimagining drug discovery through machine learning and large-scale experiment automation. Previously, she was the COO of Enlitic, a startup that uses deep learning to improve clinical diagnostics in medical imaging. Before this, she was the Innovation Director at one of the largest centers at the University of California, Berkeley, where she helped scale and spin out new social-impact technologies. Lina has been recognized on MIT Technology Review's ``TR35`` annual list of the world's top innovators for her work in open science. Her writings have been published in the New York Times, Washington Post, Science, and Make Magazine. Lina has a PhD in biomedical engineering from the ETH Zurich.

Birgit Schoeberl

Global Head Modeling and Simulation, PK Sciences, Novartis

Dr. Birgit Schoeberl currently serves as Global Head of Modeling and Simulation, PK Sciences at Novartis. Before joining Novartis, Birgit served as interim Senior Vice President, Scientific Value, at GNS Healthcare. During her time at GNS, she focused on applying causal machine learning to drug development. Prior to GNS, she was a member of the founding team at Merrimack Pharmaceuticals and where she spent over 12 years in different roles. In her latest role as Head of Discovery and Early Development, she gained broad experience in oncology drug discovery and development. Birgit and her leadership team were responsible for multiple preclinical and early clinical programs.

Birgit received her Chemical Engineering degree from the Technical University in Karlsruhe, Germany, and her Ph.D. in Biological Engineering from the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. She was a post-doctoral fellow in the laboratories of Douglas Lauffenburger and Peter Sorger in the Biological Engineering Department at MIT.

Naheed Kurji

President and CEO, Cyclica

Leslie Cousens

Director of Translational Medicine, AstraZeneca

Constantine Kreatsoulas

Director of Molecular Design US, GSK

Sameen Desai

Director of Pharmacovigilance Innovation, Celgene

Sameen has over 20 years of experience in Pharmaceutical Industry. He has a degree in Chemical Engineering, a Masters in Business Administration and a Masters in Information Systems. He has worked in several functions including manufacturing, IT, regulatory and quality. He is a Senior Director at Celgene with a focus on Innovation within Pharmacovigilance(PV). He has authored several publications around use of AI & emerging technology within PV.

Gabriel Musso

Chief Scientific Officer, BioSymetrics

Experienced data scientist and award-winning educator. Chief Scientific Officer of BioSymetrics, Gabe is responsible for pioneering the use of artificial intelligence for biomedical research. Gabe’s experience includes using machine learning frameworks to predict gene and small molecule function, and identification of disease-causal genes using large-scale genomic datasets.

Agenda

Click to download our full event agenda.

8:00    Registration, Breakfast & Networking
9:00     Chair’s Opening Remarks & Setting the Scene

Lina Williamson, Founder & Chief Innovation Officer, Translational Medicine Accelerator

9:10  Presentation: Intelligent Systems for Discovery, Translation and Implementation

Calum Macrae, Vice Chair of Scientific Innovation, Brigham and Women’s Hospital & Harvard Medical School

9:35    Presentation by Cyclica 

Naheed Kurji, President and CEO, Cyclica

10:00   Panel Discussion and Open Q&A: Is AI Always Going to be Limited by Data and is Collaboration the Key to Tackle this Issue?

Pat Walters, Senior Vice President, Computation, Relay Therapeutics
Gabrial Musso, Chief Scientific Officer, BioSymetrics
Lina Nilsson, Senior Director of Data Science Product, Recursion Pharmaceuticals
Vanita Sood, Global Head of Drug Structure, Prediction & Design, EMD Serono

10:40    Morning Refreshments & Speed Networking

Utilize this “speed dating” style networking session to make connections with over half the audience and speaker faculty in under an hour. Introduce and swap business cards with as many peers as possible to follow-up later on for a more detailed conversation

11:30  Presentation: Is Generating Your Own Data The Key To Using AI For Drug Discovery and Development Efficiently and Effectively?

Lina Nilsson, Senior Director of Data Science Product, Recursion Pharmaceuticals

11:55  Presentation: How To Ensure We Are Using AI The “Right” Way

Brian Martin, Head of AI, AbbVie

12:20    Panel Discussion and Open Q&A: When and Where is the Right Time to Use AI

Prasanna Rao, Head, A.I. and Data Science, Data Monitoring and Management, Pfizer
Sameen Desai, Director of Pharmacovigilance Innovation, Celgene
Leo Rodrigues, Vice President, AI and Machine Learning, Berg Health

1:00    Long-Table Lunch & Networking
Interactive Workshops

During these intimate breakout sessions, attendees will discuss the key questions surrounding AI and machine learning in pharma. Through deep-dive discussions, examples and peer-to-peer learning, these interactive workshops will allow attendees to uncover answers to questions that are not possible through presentations and panels… The topics in session A and B will remain the same;  giving you the opportunity to participate in two sessions. You are spoilt for choice!

2:00    Workshop Sessions A:
Workshop 1A:
Understanding the Importance of Clean, Usable Data and Underpinning the Significance of Data Sharing

The final product yielded by artificial intelligence in drug discovery and development is typically only as good as the initial data fed into the machines.
This workshop will allow you to deep dive into the importance of clean and usable data within this data-driven industry and help produce the framework in sharing data between pharma, biotech and the patient-data industry.

Workshop 2A:
Practical & Relevant Applications of Artificial Intelligence

This workshop will allow you to be fully clued up on what specific differences need to be considered when it comes to practical applications of AI in Drug discovery and development.

2:40    Workshop Sessions B: Time to Switch!
Workshop 1B:
Understanding the Importance of Clean, Usable Data and Underpinning the Significance of Data Sharing

The final product yielded by artificial intelligence in drug discovery and development is typically only as good as the initial data fed into the machines.
This workshop will allow you to deep dive into the importance of clean and usable data within this data-driven industry and help produce the framework in sharing data between pharma, biotech and the patient-data industry.

Workshop 2B:
Practical & Relevant Applications of Artificial Intelligence

This workshop will allow you to be fully clued up on what specific differences need to be considered when it comes to practical applications of AI in Drug discovery and development.

3:20    Afternoon Refreshments
Use Cases – How is AI Being Used in the Field for More Specialised Tasks
4:00  Presentation: Inventing Better Drugs – Use of AI & Machine Learning in Small Molecule & Biologics Discovery

Vanita Sood, Global Head of Drug Structure, Prediction & Design, EMD Serono

4:25  Presentation: Personalized Precision Medicine, A Patient-Scientist Perspective

Lina Williamson, Founder & Chief Innovation Officer, Translational Medicine Accelerator

Looking Ahead and Critical Questions
4:50  Panel Discussion and Open Q&A: With Artificial Intelligence at the Peak of its Hype Curve, Can Machine Learning Live Up to Expectations?

Birgit Schoeberl, Global Head Modeling and Simulation, PK Sciences, Novartis
Leslie Cousens, Director of Translational Medicine, AstraZeneca
Constantine Kreatsoulas, Director of Molecular Design US, GSK

5:30    Chair’s Closing Remarks

Lina Williamson, Founder and Chief Innovation Officer, Translational Medicine Accelerator

5:40    Drinks Reception
6:40    Close of 3rd Annual AI in Pharma Summit

The Hyatt Regency Hotel, Boston

 

(Boston, MA)

This year we have partnered with the Hyatt Regency Hotel in downtown Boston, MA.

Following the tradition of hosting the AI in Pharma Summit in inspiring venues, the 2019 summit is being hosted in this excellent, modern hotel right in the heart of the city.

Come before the event to explore the city, or why not stay afterwards to relax a little. Either way, the Hyatt Regency has everything you might need.

Details of the venue will be included in the welcome pack following registration.

Registration

Sponsorship

The 2018 summit exceeded all expectations and the 2019 summit is attracting considerable interest.

The success of the 2018 summit was down to the high-class programme and the quality of the audience. Registrations were only accepted from applicants who were appropriate for the summit and delegates from vendor companies were not permitted.

This ensured that the audience of senior decision makers were able to meet with a selected group of relevant suppliers. Our 2018 sponsors tell us that they made significant inroads into target companies and advanced their sales pipelines.

For further information, or to have an informal discussion regarding sponsorship opportunities, please contact Zanib Malik on 020 3865 9030 or zanib@greygreenmedia.com

2018 Audience Breakdown

2018 Audience Job Title

Register For The Event

For pricing and booking options please click the button to go to the registration page.
Registration